Douwe F Samplonius相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells

新型 Fab-肽-HLA-I 融合蛋白，用于重定向预先存在的抗 CMV T 细胞免疫以选择性消除癌细胞

期刊:Oncoimmunology

doi:10.1080/2162402X.2023.2207868

Isabel Britsch, Anne P van Wijngaarden, Xiurong Ke, Mark A J M Hendriks, Douwe F Samplonius, Emily M Ploeg, Wijnand Helfrich

发表日期：2023

文献求助收藏

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis

受到免疫攻击的癌细胞获得独立于髓系 CD47-SIRPα 轴的 CD47 介导的适应性免疫抵抗力

期刊:Oncoimmunology

doi:10.1080/2162402X.2021.2005344

Mark A J M Hendriks, Isabel Britsch, Xiurong Ke, Anne P van Wijngarden, Douwe F Samplonius, Emily M Ploeg, Wijnand Helfrich

发表日期：2021

文献求助收藏

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation

双特异性抗体方法针对 EGFR 定向阻断 CD47-SIRPα“不要吃我”免疫检查点，促进中性粒细胞介导的嗜中性粒细胞凋亡并增强抗原交叉呈递

期刊:Oncoimmunology

doi:10.1080/2162402X.2020.1824323

Mark A J M Hendriks, Emily M Ploeg, Iris Koopmans, Isabel Britsch, Xiurong Ke, Douwe F Samplonius, Wijnand Helfrich

细胞生物学

发表日期：2020

文献求助收藏

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

一种用于 EGFR 定向阻断 PD-1/PD-L1 免疫检查点的新型双特异性抗体

期刊:Oncoimmunology

doi:10.1080/2162402X.2018.1466016

Iris Koopmans, Djoke Hendriks, Douwe F Samplonius, Robert J van Ginkel, Sandra Heskamp, Peter J Wierstra, Edwin Bremer, Wijnand Helfrich

发表日期：2018

文献求助收藏

A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members

一种用于肿瘤选择性递送和激活 TNF 超家族成员的多功能预定位方法

期刊:Scientific Reports

影响因子:3.8

doi:10.1038/s41598-017-13530-w

Yuan He, Peter E van Bommel, Douwe F Samplonius, Edwin Bremer, Wijnand Helfrich

发表日期：2017

文献求助收藏

CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab

使用双特异性抗体衍生物对 CD47-SIRPα 的 CD20 选择性抑制“不要吃我”信号传导可增强达雷木单抗、阿仑单抗和奥比妥珠单抗的抗癌活性

期刊:Oncoimmunology

doi:10.1080/2162402X.2017.1386361

Peter E van Bommel, Yuan He, Ilona Schepel, Mark A J M Hendriks, Valerie R Wiersma, Robert J van Ginkel, Tom van Meerten, Emanuele Ammatuna, Gerwin Huls, Douwe F Samplonius, Wijnand Helfrich, Edwin Bremer

发表日期：2017

文献求助收藏

Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction

程序性死亡配体 1 (PD-L1) 靶向 TRAIL 将 PD-L1 介导的检查点抑制与 TRAIL 介导的凋亡诱导相结合

期刊:Oncoimmunology

doi:10.1080/2162402X.2016.1202390

Djoke Hendriks, Yuan He, Iris Koopmans, Valerie R Wiersma, Robert J van Ginkel, Douwe F Samplonius, Wijnand Helfrich, Edwin Bremer

细胞生物学

发表日期：2016

文献求助收藏

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy

高级别浆液性卵巢癌中的 CD103+ 上皮内 T 细胞是表型多样的 TCRαβ+ CD8αβ+ T 细胞，可以作为癌症免疫治疗的靶点

期刊:Oncotarget

doi:10.18632/oncotarget.12077

Fenne L Komdeur, Maartje C A Wouters, Hagma H Workel, Aline M Tijans, Anouk L J Terwindt, Kim L Brunekreeft, Annechien Plat, Harry G Klip, Florine A Eggink, Ninke Leffers, Wijnand Helfrich, Douwe F Samplonius, Edwin Bremer, G Bea A Wisman, Toos Daemen, Evelien W Duiker, Harry Hollema, Hans W Nijman,

发表日期：2016

文献求助收藏

The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux

上皮极性调节剂 LGALS9/galectin-9 诱导 KRAS 突变结肠癌中致命的自噬受阻，这种自噬依赖于升高的基础自噬通量

期刊:Autophagy

影响因子:14.6

doi:10.1080/15548627.2015.1063767

Valerie R Wiersma, Marco de Bruyn, Yunwei Wei, Robert J van Ginkel, Mitsuomi Hirashima, Toshiro Niki, Nozomu Nishi, Jin Zhou, Simon D Pouwels, Douwe F Samplonius, Hans W Nijman, Paul Eggleton, Wijnand Helfrich, Edwin Bremer

发表日期：2015

文献求助收藏

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

型凝集素样分子-1 (CLL1) 靶向 TRAIL 增强粒细胞的杀肿瘤活性并增强治疗性抗体依赖性细胞介导的细胞毒性

影响因子:5.6

doi:10.1080/19420862.2015.1007811

Valerie R Wiersma, Marco de Bruyn, Ce Shi, Marloes J M Gooden, Maartje C A Wouters, Douwe F Samplonius, Djoke Hendriks, Hans W Nijman, Yunwei Wei, Jin Zhou, Wijnand Helfrich, Edwin Bremer

发表日期：2015

文献求助收藏